223 related articles for article (PubMed ID: 20511169)
21. [Meningeal infiltration in multiple myeloma. Study of a new case and literature review].
Escorsell A; López-Guillermo A; Blade J; Villamor N; Massanes F; Montserrat E; Rozman C
Rev Clin Esp; 1992 Dec; 191(9):478-80. PubMed ID: 1488536
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience.
Warzocha K; Kraj M; Pogłód R; Kwaśniak B
Acta Pol Pharm; 2008; 65(6):753-6. PubMed ID: 19172860
[No Abstract] [Full Text] [Related]
23. [PAD regimen for relapsed or refractory patients with multiple myeloma].
Zhang YQ; Liang R; Bai QX; Zhang T; Yang L; Wang YW; Wang WQ; Gu HT; Shu MM; Zhu HF; Bai YN; Chen XQ
Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):260-3. PubMed ID: 19731828
[TBL] [Abstract][Full Text] [Related]
24. Multiple myeloma with multiple and bulky extramedullary plasmacytomas as initial presentation.
SAWADA T; NAJIMA Y; OHASHI K; KATO I; MIYAZAWA M; NAKANO M; KOBAYASHI T; YAMASHITA T; AKIYAMA H; SAKAMAKI H
Rinsho Ketsueki; 2009 Nov; 50(11):1635-40. PubMed ID: 20009440
[TBL] [Abstract][Full Text] [Related]
25. DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
Lemaire O; Attal M; Bourin P; Laroche M
Eur J Haematol; 2010 Mar; 84(3):276-7. PubMed ID: 19891699
[No Abstract] [Full Text] [Related]
26. A case of aggressive multiple myeloma with cleaved, multilobated, and monocytoid nuclei, and no serum monoclonal gammopathy.
Yeh YA; Pappas AA; Flick JT; Butch AW
Ann Clin Lab Sci; 2000 Jul; 30(3):283-8. PubMed ID: 10945569
[TBL] [Abstract][Full Text] [Related]
27. Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
Dasanu CA; Reale MA; Bauer F
Leuk Res; 2010 Jul; 34(7):e178-80. PubMed ID: 20079532
[No Abstract] [Full Text] [Related]
28. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG
Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652
[TBL] [Abstract][Full Text] [Related]
29. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
30. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
Chim CS
Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
[No Abstract] [Full Text] [Related]
31. Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
Moriuchi M; Ohmachi K; Kojima M; Tsuboi K; Ogawa Y; Nakamura N; Ando K
Tokai J Exp Clin Med; 2010 Apr; 35(1):17-20. PubMed ID: 21319020
[TBL] [Abstract][Full Text] [Related]
32. Intracranial multiple myeloma involving the dura.
Tsang CS; Ho LC; Tan TC
J Clin Neurosci; 2006 Jan; 13(1):122-3. PubMed ID: 16410212
[TBL] [Abstract][Full Text] [Related]
33. [Bence Jones type multiple myeloma showing diffuse infiltration to the dura mater by myeloma cells].
Nomoto N; Saito H; Kashimura M; Aoki S; Shibata A
Rinsho Ketsueki; 1995 Jul; 36(7):694-9. PubMed ID: 7563599
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
[TBL] [Abstract][Full Text] [Related]
35. Frontline regimens for multiple myeloma patients.
Lonial S
Clin Adv Hematol Oncol; 2010 May; 8(5):331-2. PubMed ID: 20551891
[No Abstract] [Full Text] [Related]
36. The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.
Benevolo G; Larocca A; Gentile M; Pregno P; Gay F; Botto B; Frairia C; Evangelista A; Morabito F; Boccadoro M; Vitolo U; Palumbo A
Cancer; 2011 May; 117(9):1884-90. PubMed ID: 21509765
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Kim YK; Sohn SK; Lee JH; Yang DH; Moon JH; Ahn JS; Kim HJ; Lee JJ;
Ann Hematol; 2010 May; 89(5):475-82. PubMed ID: 19921192
[TBL] [Abstract][Full Text] [Related]
38. [Effect of Velcade combined with Dexamethasone on multiple myeloma].
He Q; Zhao X; He Y; Tan D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 35(8):864-7. PubMed ID: 20818081
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
40. [Meningeal plasmacytoma: delayed diagnosis with sequelae].
Buchbender C; Antoch G; Nawatny J
Rofo; 2011 Aug; 183(8):761-2. PubMed ID: 21442568
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
